- Home
- ESPR vs TSHA Comparison
ESPR vs TSHA Comparison
Compare ESPR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- TSHA
- Stock Information
- Founded
- ESPR 2008
- TSHA 2019
- Country
- ESPR United States
- TSHA United States
- Employees
- ESPR N/A
- TSHA N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- TSHA Health Care
- Exchange
- ESPR Nasdaq
- TSHA Nasdaq
- Market Cap
- ESPR 208.1M
- TSHA 728.4M
- IPO Year
- ESPR 2013
- TSHA 2020
- Fundamental
- Price
- ESPR $1.18
- TSHA $2.45
- Analyst Decision
- ESPR Buy
- TSHA Strong Buy
- Analyst Count
- ESPR 6
- TSHA 5
- Target Price
- ESPR $6.50
- TSHA $8.20
- AVG Volume (30 Days)
- ESPR 3.2M
- TSHA 3.4M
- Earning Date
- ESPR 08-11-2025
- TSHA 08-11-2025
- Dividend Yield
- ESPR N/A
- TSHA N/A
- EPS Growth
- ESPR N/A
- TSHA N/A
- EPS
- ESPR N/A
- TSHA N/A
- Revenue
- ESPR $259,574,000.00
- TSHA $7,224,000.00
- Revenue This Year
- ESPR $4.07
- TSHA N/A
- Revenue Next Year
- ESPR N/A
- TSHA N/A
- P/E Ratio
- ESPR N/A
- TSHA N/A
- Revenue Growth
- ESPR 12.99
- TSHA N/A
- 52 Week Low
- ESPR $0.69
- TSHA $1.05
- 52 Week High
- ESPR $3.94
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- ESPR 61.39
- TSHA 48.54
- Support Level
- ESPR $0.95
- TSHA $2.25
- Resistance Level
- ESPR $1.06
- TSHA $2.51
- Average True Range (ATR)
- ESPR 0.08
- TSHA 0.15
- MACD
- ESPR -0.00
- TSHA -0.03
- Stochastic Oscillator
- ESPR 83.33
- TSHA 48.78
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.